Pharmacological profile of the new inotropic agent AT-11

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 224-230

  Lee, An Sheng ^a   Wu, Tian Shung ^b,c   Su, Ming Jai ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

Cardiac glycoside; Digitalis; Heart failure; Na K ATPase; Sodium pump

Indexed keywords

AT 11; INOTROPIC AGENT; OUABAIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SYMPATHETIC TONE; TOXICITY TESTING; VAGUS REFLEX;

ANIMALS; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; GUINEA PIGS; HEART RATE; LACTONES; MALE; MYOCARDIAL CONTRACTION; OUABAIN; POLYCYCLIC COMPOUNDS; SODIUM-POTASSIUM-EXCHANGING ATPASE; SYMPATHETIC NERVOUS SYSTEM; VAGUS NERVE;

EID: 37649020908     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.056     Document Type: Article

References (22)

1. Akera T., and Ng Y.C. Digitalis sensitivity of Na+,K(+)-ATPase, myocytes and the heart. Life Sci. 48 (1991) 97-106
2. Chen W.P., Su M.J., and Hung L.M. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur. J. Pharmacol. 554 (2007) 196-204
3. Chierchia S., and Deferrari L. Cell transplantation: a novel perspective in the treatment of heart failure. Ital. Heart J. 5 Suppl 6 (2004) 108S-115S
4. Cleland J.G., Khand A., and Clark A. The heart failure epidemic: exactly how big is it?. Eur. Heart J. 22 (2001) 623-626
5. Demiryurek A.T., and Demiryurek S. Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton. Autacoid Pharmacol. 25 (2005) 35-52
6. Gadsby D.C., Kimura J., and Noma A. Voltage dependence of Na/K pump current in isolated heart cells. Nature 315 (1985) 63-65
7. Gheorghiade M., and Pitt B. Digitalis Investigation Group (DIG) trial: a stimulus for further research. Am. Heart J. 134 (1997) 3-12
8. Hauptman P.J., and Kelly R.A. Digitalis. Circulation 99 (1999) 1265-1270
9. Isenberg G., and Klockner U. Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium". Pflugers Arch. 395 (1982) 6-18
10. Khatter J.C., Agbanyo M., Hoeschen R.J., Navaratnam S., and Bains R. Digitalis-induced mechanical toxicity: protection by slow Ca++ channel blockers. J. Pharmacol. Exp. Ther. 239 (1986) 206-210
11. Khatter J.C., Agbanyo M., Navaratnam S., Nero B., and Hoeschen R.J. Digitalis cardiotoxicity: cellular calcium overload a possible mechanism. Basic Res. Cardiol. 84 (1989) 553-563
12. Lee A.-S., Wu T.-S., and Su M.-J. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am. J. Cardiol. 83 (1999) 1A-38A
13. McGarry S.J., and Williams A.J. Digoxin activates sarcoplasmic reticulum Ca(2+)-release channels: a possible role in cardiac inotropy. Br. J. Pharmacol. 108 (1993) 1043-1050
14. Mengi S.A., and Dhalla N.S. Carnitine palmitoyltransferase-I, a new target for the treatment of heart failure: perspectives on a shift in myocardial metabolism as a therapeutic intervention. Am. J. Cardiovasc. Drugs 4 (2004) 201-209
15. Micheletti R., Mattera G.G., Rocchetti M., Schiavone A., Loi M.F., Zaza A., Gagnol R.J., De Munari S., Melloni P., Carminati P., Bianchi G., and Ferrari P. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride (PST2744). J. Pharmacol. Exp. Ther. 303 (2002) 592-600
16. Rocchetti M., Besana A., Mostacciuolo G., Ferrari P., Micheletti R., and Zaza A. Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms. J. Pharmacol. Exp. Ther. 305 (2003) 765-771
17. Sagawa T., Sagawa K., Kelly J.E., Tsushima R.G., and Wasserstrom J.A. Activation of cardiac ryanodine receptors by cardiac glycosides. Am. J. Physiol. 282 (2002) H1118-H1126
18. Stewart S., MacIntyre K., Hole D.J., Capewell S., and McMurray J.J. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail. 3 (2001) 315-322
19. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336 (1997) 525-533
20. Valente R.C., Capella L.S., Monteiro R.Q., Rumjanek V.M., Lopes A.G., and Capella M.A. Mechanisms of ouabain toxicity. FASEB J. 17 (2003) 1700-1702
21. von Harsdorf R., Poole-Wilson P.A., and Dietz R. Regenerative capacity of the myocardium: implications for treatment of heart failure. Lancet 363 (2004) 1306-1313
22. Wahed M.I., Watanabe K., Ma M., Nakazawa M., Takahashi T., Hasegawa G., Naito M., Yamamoto T., Kodama M., and Aizawa Y. Effects of pranidipine, a novel calcium channel antagonist, on the progression of left ventricular dysfunction and remodeling in rats with heart failure. Pharmacology 72 (2004) 26-32